No Data
No Data
ImmunityBio Is Maintained at Buy by D. Boral Capital
Express News | Immunitybio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (Aua) Annual Meeting
ImmunityBio, Inc. (NASDAQ:IBRX) Chief Scientific Officer Patrick Soon-Shiong's Holdings Dropped 15% in Value as a Result of the Recent Pullback
H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $8
ImmunityBio Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
ImmunityBio's Strategic Growth and Innovation in Immunotherapy: A Buy Recommendation